US Daily Brief: Today‘s Research – July 17, 2026

Research evidence excerpt

US Daily Brief: Today‘s Research – July 17, 2026

Global Research

17 July 2026ab

US Daily Brief Equities

AmericasToday's Research – July 17, 2026

Joseph Parkhill

Product Manager

Copper - Copper: Data Centre Download (Daniel Major) joseph.parkhill@ubs.com

+1-212-713 3716

We incorporate UBS updated forecasts for global Data Centre capacity additions into

our copper demand forecasts and explore the impacts on the copper market Peter Lennox-King

peter.lennox-king@ubs.com

Franco-Nevada Corp (FNV, Buy, $280) - Growth upside and hidden value after Cobre +1-212-713 3215

Panama restart (Daniel Major)

Ryan BellCobre Panama restart remains the key near-term catalyst for FNV. Looking beyond CP

restart, in our view FNV's medium-term growth optionality is undervalued ryan-b.bell@ubs.com

+1-212-713 1233

GE Aerospace (GE, Buy, $435 from $426) - Strong fundamentals continue even

amidst declining flight hours (Gavin Parsons)

We raise our estimates slightly and don't see any major detractors to the long-term bull

case

Eli Lilly and Co (LLY, Buy, $1425) - *Slides* GLP-1 Generics? We see only ~25-30%

capacity of market meanwhile LLY has Gen 3.0 Reta and Amylin Coming at 25-29%

weight loss... (Michael Yee)

A key long term debate on LLY is whether generic GLP1 (ie Semaglutide from NVO) pot'l

coming to US/EU in 2031+ could significantly undercut pricing in the branded GLP1

market and hit revenues for market share leader LLY post 2030+ on protected drugs like

Zepbound, etc

Eli Lilly and Co (LLY, Buy, $1425) - Another tuck in deal to bolster their neuro franchise

- aligns with Dave Ricks recent commentary (Michael Yee)

Eli Lilly announced it will acquire ATAI (AtaiBeckley) for ~$2.8B upfront, and up to $1B in

CVR

Online Sports Betting and Gaming - The British Are Coming (PART 2) (Robin Farley)